Spear Pharmaceuticals   Report issue

For profit Phase 3
Founded: Randolph NJ United States (1993)
Status: No NME R&D (1993)

Organization Overview

First Clinical Trial
2009
NCT01243450
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

fluorouracil (efudex) (1 trial)

tretinoin (Retin-A) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Keratosis (Phase 3)

Keratosis, Actinic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2